The field of human subjects protections lost a treasured member last month with the passing of Jerry Castellano, BS, PharmD, CIP, on January 1, 2022. Read more
16Feb2022
8Feb2022
PRIM&R calls for NIH to deepen engagement with the public on data sharing rules
Tags:
8 Feb
No comments
PRIM&R is calling on NIH to improve its outreach to the public in determining new rules and procedures for sharing their genetic data when participating in research. We also ask for rigorous study of methods for protecting data privacy outside of deidentification, which can no longer be relied upon by itself to permanently protect data. Read more
2Feb2022
Increasing Public Understanding and Acceptance of Animal Studies: Where to Begin?
Tags:
2 Feb
No comments
The more Americans understand the biomedical research process, the more likely they are to support necessary health studies in animals. While a growing number of research organizations recognize the need for additional public engagement, many have no idea where to begin, so here are some effective steps to consider. Read more
27Jan2022
Research Ethics Roundup: failure to disclose conflicts, ethics of human challenge trials, and more
Tags:
27 Jan
No comments
This edition of Research Ethics Roundup covers study authors failing to disclose conflict of interest, ethics of COVID-19 human challenge trials, a Moderna trial volunteer objecting to their business practices, and the upcoming vote on the Swiss animal testing ban Read more
26Jan2022
This January, PRIM&R welcomed three new members to our Board of Directors and two new members to our Membership Committee. These members exemplify service to the field of research ethics and promise to be strong stewards of PRIM&R’s mission in the years to come. Read more
20Jan2022
Conducting Risk Benefit Analysis of Secondary Use Data from Mobile Health Apps
Tags:
20 Jan
No comments
The data collected from mobile mental health apps has promising benefit toward the field of mental health. The risks are usually limited to breach of confidentiality and investigators mitigate those risks by implementing processes to protect access to the data. In studies involving algorithms and personalized medicine, the risks increase. So, how do IRBs determine when risks outweigh the benefits? Read more